Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis
Conclusions
Natalizumab trough drug levels can decrease after switching from natalizumab intravenous to SC administration. We advise to monitor trough drug levels in patients with low natalizumab drug levels during intravenous treatment, patients with higher body mass index or patients on extended treatment intervals who switch to SC administration of natalizumab. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 15, 2023 Category: Neurosurgery Authors: Toorop, A. A., van Kempen, Z. L. E., Steenhuis, M., Nielsen, J., Sinnige, L. G. F., van Dijk, G., Roosendaal, C. M., Arnoldus, E. P. J., Hoitsma, E., Lissenberg-Witte, B. I., de Jong, B. A., Oosten, B. W. v., Strijbis, E. M. M., Uitdehaag, B. M. J., Rispe Tags: JNNP Patients' choice Multiple sclerosis Source Type: research
AHSCT vs Fingolimod, Natalizumab, and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
This comparative effectiveness research study compares autologous hematopoietic stem cell transplant (AHSCT) vs fingolimod, natalizumab, and ocrelizumab for patients with relapsing-remitting multiple sclerosis. (Source: JAMA Neurology)
Source: JAMA Neurology - May 15, 2023 Category: Neurology Source Type: research
Natalizumab extended-interval dosing in a real-life setting
Natalizumab is a high-efficacy therapy for recurrent multiple sclerosis (RMS) with a four-week administration interval. Controlled trials have shown that extending this interval to six weeks led to better safety without increasing the risk of relapse. We aimed to analyze the safety of extending the natalizumab interdose interval from 4 to 6 weeks in a real-life setting. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - May 13, 2023 Category: Neurology Authors: Lina Jeantin, Marine Boudot de la Motte, Romain Deschamps, Antoine Gueguen, Olivier Gout, Augustin Lecler, Caroline Papeix, Caroline Bensa Tags: Clinical short communication Source Type: research
Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterised concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37142541 | DOI:10.1016/j.farma.2023.03.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - May 4, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterised concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37142541 | DOI:10.1016/j.farma.2023.03.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - May 4, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
ConclusionsThe JCV status can be used as a natural experiment to compare treatment arms with a low selection bias. In our study, switching to OCR versus NTZ continuation led to similar disease activity outcomes. (Source: Journal of Neurology)
Source: Journal of Neurology - April 30, 2023 Category: Neurology Source Type: research
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
ConclusionThe effectiveness of natalizumab in patients with active relapsing –remitting multiple sclerosis (RRMS) could be confirmed in our real-world cohort even after follow-up of up to 14 years, though after year 10, there were less than 100 remaining patients. A low number of AE were reported in this nationwide registry study, establishing Natalizumab’s favourable s afety profile during long-term use. (Source: Journal of Neurology)
Source: Journal of Neurology - April 19, 2023 Category: Neurology Source Type: research
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
In this study, we report that in patients with MS, NTZ treatment is associated with an enhanced activation status of peripheral monocytes.
Results
Expression of 2 independent activation markers, CD69 and CD150, was significantly higher on blood monocytes from NTZ-treated patients when compared with those from matched untreated patients with MS, while other properties such as cytokine production remained unchanged.
Discussion
These findings consolidate the concept that peripheral immune cells remain fully competent on NTZ treatment, an excellent asset rare among MS treatments. However, they also suggest that NTZ may exert...
Source: Neurology Neuroimmunology and Neuroinflammation - April 18, 2023 Category: Neurology Authors: Frisch, E. S., Häusler, D., Weber, M. S. Tags: Multiple sclerosis Clinical/Scientific Note Source Type: research
Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
CONCLUSIONS: Real-world costs increased after patients started/switched to infusible DMTs. Drug cost is the main driver for the total costs, which varied substantially by site of care. Controlling drug cost markups and using home setting for infusion can reduce costs in the treatment of MS patients.PMID:36970763 | DOI:10.1080/13696998.2023.2194185 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 27, 2023 Category: Health Management Authors: Enrique Alvarez Kavita V Nair Hiangkiat Tan Kapil Rathi Nicole B Gabler Eric M Maiese Chinmay Deshpande Qiujun Shao Source Type: research
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing –Remitting Multiple Sclerosis: STRIVE Data Analysis
ConclusionThese results highlight the effectiveness and safety of natalizumab in patients with early RRMS who self-identified as Black/AA or Hispanic/Latino.ClinicalTrials.govNCT01485003. (Source: Neurology and Therapy)
Source: Neurology and Therapy - March 26, 2023 Category: Neurology Source Type: research
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies
ConclusionsAfter two doses of SARS-CoV-2 vaccination, a high response yield was achieved, except in patients who had received fingolimod. The effects of fingolimod on cellular immunity persisted for more than 2 years after a change to ocrelizumab (which, in contrast, conserved cellular immunity). Our results confirmed the need to find alternative protective measures for fingolimod-treated people and to consider the possible failure to provide protection against SARS-CoV-2 when switching from fingolimod t o ocrelizumab. (Source: Journal of Neurology)
Source: Journal of Neurology - March 18, 2023 Category: Neurology Source Type: research
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
ConclusionsThe JCV status can be used as a natural experiment to compare treatment arms with a low selection bias. In our study, switching to OCR versus NTZ continuation led to similar disease activity outcomes. (Source: Journal of Neurology)
Source: Journal of Neurology - March 13, 2023 Category: Neurology Source Type: research
Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis
ConclusionsStudies on the effect of drugs and non-pharmacological treatments for MS on sleep are still insufficient and there is a lack of investigations on the most recent therapies. However, there is preliminary evidence that melatonin, chronotherapy, cognitive-behavioral therapy, and non-invasive brain stimulation techniques might be further assessed as adjuvant therapies, thus representing a promising field of research. (Source: Journal of Neurology)
Source: Journal of Neurology - March 11, 2023 Category: Neurology Source Type: research
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing –remitting multiple sclerosis in Austria
ConclusionsHorizontal switching after a platform therapy resulted in a higher relapse and interrupt probability and was associated with a trend towards less EDSS improvement comparing to vertical switching in Austrian RRMS patients. (Source: Journal of Neurology)
Source: Journal of Neurology - March 2, 2023 Category: Neurology Source Type: research
A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study
CONCLUSIONS: Based on a large real-world cohort, our results confirm the durable reduction of the ARR described in pivot studies. Switching from moderate-efficacy DMT to fingolimod decreased the relapse risk. Switching patients from high-efficacy DMT increased risk of relapse, but the overall five-years ARR remained stable.PMID:36841644 | DOI:10.1016/j.neurol.2022.11.012 (Source: Revue Neurologique)
Source: Revue Neurologique - February 25, 2023 Category: Neurology Authors: L Gauer K Bigaut É Berger M Debouverie T Moreau J de S èze Source Type: research
